loading...| Preferred Name |
norgestrel |
|
| Synonyms |
Ovrette |
|
| Definitions |
A synthetic progestin commonly used alone or in combination with an estrogen for contraception. Norgestrel suppresses the secretion of luteinizing and follicle-stimulating hormones (LH and FSH), thickens cervical mucus, and slows the transit of ova through the fallopian tubes. This agent also exhibits antiproliferative activity in endometrial tissue and may exhibit chemopreventive and antineoplastic activities in endometrial carcinoma. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C703" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C703" NCI Thesaurus) |
|
| ID |
http://purl.bioontology.org/ontology/PDQ/CDR0000039310 |
|
| altLabel |
Ovrette Wy-3707 (+/-)-13-ethyl-17alpha-hydroxy-18,19-dinorpregn-4-en-20-yne-3-one (17alpha)-13-ethyl-17-hydroxy-18,19-dinorpregn-4-en-20-yn-3-one Neogest |
|
| CAS Registry |
6533-00-2 |
|
| Component of | ||
| cui |
C0699168 C0023566 C0701266 C0699169 C0028368 |
|
| Date last modified |
2017-11-02 |
|
| definition |
A synthetic progestin commonly used alone or in combination with an estrogen for contraception. Norgestrel suppresses the secretion of luteinizing and follicle-stimulating hormones (LH and FSH), thickens cervical mucus, and slows the transit of ova through the fallopian tubes. This agent also exhibits antiproliferative activity in endometrial tissue and may exhibit chemopreventive and antineoplastic activities in endometrial carcinoma. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C703" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C703" NCI Thesaurus) |
|
| Legacy PDQ ID |
1946 |
|
| LT |
TRD |
|
| NCI ID |
C703 |
|
| notation |
CDR0000039310 |
|
| ORIG STY |
Drug/agent |
|
| prefLabel |
norgestrel |
|
| tui |
T125 T109 T121 |